3,7-Bis(tert-butylamino)heptan-2-one

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 3,7-Bis(tert-butylamino)heptan-2-one
• 英文别名: 3,7-bis(tert-butylamino)heptan-2-one
• 化学式: C₁₅H₃₂N₂O
• 分子量: 256.43
• InChiKey: ZRDSXXDFFZUVRM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  18
• 可旋转键数：
  9
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.93
• 拓扑面积：
  41.1
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• Carrier-linked treprostinil prodrugs
  申请人：Hersel Ulrich

  公开号：US10729778B2

  公开（公告）日：2020-08-04

  Prodrugs or a pharmaceutically acceptable salt thereof which comprise a covalent treprostinil carrier conjugate, as well as their pharmaceutical composition, may be used as medicaments, especially for diseases or disorders which can be treated by treprostinil, such as pulmonary arterial hypertension (PAH).

  包含共价曲普瑞替尼载体共轭物的原药或其药学上可接受的盐，以及它们的药物组合物可用作药物，特别是可通过曲普瑞替尼治疗的疾病或紊乱，如肺动脉高压（PAH）。
• Polymeric Hyperbranched Carrier-Linked Prodrugs
  申请人：Hersel Ulrich

  公开号：US20140243254A1

  公开（公告）日：2014-08-28

  The present invention relates to water-soluble carrier-linked prodrugs of formula (I), wherein POL is a polymeric moiety, each Hyp is independently a hyperbranched moiety, each moiety SP is independently a spacer moiety, each L is independently a reversible prodrug linker moiety, m is 0 or 1, each n is independently an integer from 2 to 200 and each x is independently 0 or 1. It further relates to pharmaceutical compositions comprising said water-soluble carrier-linked prodrugs and methods of treatment.
• Sustained Release Composition of Prostacyclin
  申请人：Sprogøe Kennett

  公开号：US20140303245A1

  公开（公告）日：2014-10-09

  The present invention relates to sustained release compositions of prostacyclin, as well as uses thereof, in particular for the prevention and/or treatment of pulmonary arterial hypertension.
• Carrier-Linked Treprostinil Prodrugs
  申请人：Hersel Ulrich

  公开号：US20190105400A1

  公开（公告）日：2019-04-11

  The present invention relates to prodrugs or a pharmaceutically acceptable salt thereof comprising a covalent treprostinil carrier conjugate as well as pharmaceutical composition comprising said compounds. The compounds may be used as medicaments, especially for diseases or disorders which can be treated by treprostinil, such as pulmonary arterial hypertension (PAH).